Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors 英文参考文献.docVIP

下载本文档

8
0
约4.66万字
约 11页
2017-05-13 发布于上海
举报

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors 英文参考文献.doc

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors 英文参考文献

Rousseauetal.EJNMMIResearch2011,1:20 /content/1/1/20 ORIGINAL RESEARCH OpenAccess Syndecan-1antigen,apromisingnewtargetfor triple-negativebreastcancerimmuno-PETand radioimmunotherapy.Apreclinicalstudyon MDA-MB-468xenografttumors CarolineRousseau1,2?,AnneLiseRuellan2?,KarineBernardeau2,Fran?oiseKraeber-Bodéré1,2,3,SebastienGouard2, DelphineLoussouarn4,CatherineSa?-Maurel2,AlainFaivre-Chauvet2,JohnWijdenes5,JacquesBarbet2, Jo?lleGaschet2,MichelChérel1,2 andFran?oisDavodeau2* Abstract Background:Overexpressionofsyndecan-1(CD138)inbreastcarcinomacorrelateswithapoorprognosisandan aggressivephen

您可能关注的文档

文档评论（0）

1亿VIP精品文档

更多 >

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors 英文参考文献.docVIP